The MIB is seeking to renew a licensing fee for B-hIL2RA transgenic mice, which are essential for pre-clinical research on photoimmunotherapy (PIT) targeting IL2RA-expressing regulatory T cells to improve anti-cancer immune responses. No submission timelines or budget amounts are specified. The location for performance of services is not mentioned.